Volume 2015 Supplement 1
Development of diabetes mellitus after hematopoietic stem cell transplantation for childhood leukemia
© Ah Jung et al; licensee BioMed Central Ltd. 2015
Published: 28 April 2015
We investigated clinical features of newly diagnosed diabetes mellitus (DM) after hematopoietic stem cell transplantation (HSCT) for treatment of childhood leukemia.
Between April 2009 and March 2014, total 124 patients (73 males, 51 females) were visited the clinic of pediatric endocrinology for routine follow-up check after HSCT for leukemia. Among them, five patients developed DM (4 males, 1 female). We retrospectively reviewed medical charts including laboratory findings.
Three patients were diagnosed as acute lymphoblastic leukemia who received total body irradiation and chemotherapy. The other two patients were diagnosed as acute myeloblastic leukemia. The mean age at HSCT was 8.0 ± 4.2 years. Four out of five patients developed chronic graft-versus-host disease (GVHD) and treated with steroid more than 2 years. The mean age at diagnosis of DM was 15.8 ± 1.8 years and the time interval between HSCT and DM was 7.8 ± 4.4 years. Three patients showed obesity depend on body mass index (>95th percentile for sex and age). No one showed antibodies related with pancreatic β-cell. All five patients showed hyperinsulinemia with mean fasting insulin levels at diagnosis of DM was 13.3 ± 9.2 μIU/mL. The mean homeostasis model assessment of insulin resistance index (HOMA-IR) of patients was 4.39 ± 2.01.
GVHD, long-term steroid treatment and insulin resistance seem to be close related to develop of DM after HSCT for treatment of childhood leukemia.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.